The U.S. Court of Appeals for the Third Circuit has upheld a Pennsylvania federal judge’s dismissal of antitrust claims against GlaxoSmithKline over a patent infringement settlement with generic drugmakers allegedly aimed at delaying market entry of generic versions of the popular antidepressant Wellbutrin XL.
But the appeals court’s reasoning for upholding those rulings has not yet been revealed to the public. The court temporarily issued its Wednesday opinion under seal and, in a separate order, gave the parties until Aug. 15 to agree on proposed redactions.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
